Gene‑edited HPSCs programmed to make therapeutic antibodies and proteins show long‑lasting, boostable immunity in mouse models.

Harnessing technology transferred from VTT Technical Research Centre of Finland, Proteins.1 is developing a PCR-like ...

AACR chairs Paul Mischel and Alice Shaw shared insights with GEN on the key themes shaping this year’s program.

New protocol generated glucose-responsive SC-islets from eight hPSC lines tested, demonstrating potential for autologous ...

Rarely, some nanoparticles that enter a cell undergo an unexpected transformation, acquiring a coating known as a “condensate ...

Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.

The new Fujifilm Biotechnologies QC Lab features ventilation systems, personnel, and material airlocks, and an open‑plan layout.

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

As is true in most industries, adoption of AI and machine learning (ML) is real and accelerating across the biopharma industry. However, most use cases center around applicatio ...

Researchers say knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.

An iPSC manufacturing strategy for cell therapies drops the cost of goods sold to about $5,000 per dose, down from $115,000 per dose for autologous therapeutics and $40,000 per dose for allogeneic ...

PerturbFate can systematically map how diverse disease-associated genetic variations reshape cells to understand complex diseases, like cancer.